Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study

被引:0
|
作者
Marina Amaral de Ávila Machado
Cristiano Soares de Moura
Steve Ferreira Guerra
Jeffrey R. Curtis
Michal Abrahamowicz
Sasha Bernatsky
机构
[1] Research Institute of McGill University Health Centre,Division of Clinical Epidemiology
[2] University of Alabama at Birmingham,Division of Clinical Immunology and Rheumatology
[3] Research Institute of McGill University Health Centre,Department of Epidemiology, Biostatistics and Occupational Health
关键词
Rheumatoid arthritis; Tofacitinib; Disease-modifying antirheumatic drug; Biologic therapy; Comparative effectiveness research;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 50 条
  • [21] Investigating the Effectiveness of Combined Tofacitinib and Cyclophosphamide Therapy in Rheumatoid Arthritis
    Li, Shuyao
    Guan, Tong
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 86 : 245 - 253
  • [22] COST-EFFECTIVENESS OF TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS IN CHINA
    Wang, B. C.
    Chen, Y.
    Furnback, W.
    Wu, Q.
    Dong, P.
    VALUE IN HEALTH, 2018, 21 : S197 - S197
  • [23] Real-world effectiveness of tofacitinib in patients with rheumatoid arthritis: a prospective observational study
    Shouval, A.
    Lidar, M.
    Reitblat, T.
    Zisman, D.
    Balbir-Gurman, A.
    Mashiach, T.
    Almog, R.
    Elkayam, O.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (06) : 1378 - 1384
  • [24] IS BETTER AND SAFER TOFACITINIB AS A FIRST LINE OF TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS? - A COHORT STUDY
    Valencia, O.
    Cabrera, M.
    Rodriguez, F.
    Santos-Moreno, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1939 - 1939
  • [25] Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis
    Curtis, J. R.
    Schulze-Koops, H.
    Takiya, L.
    Mebus, C. A.
    Terry, K. K.
    Biswas, P.
    Jones, T. V.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2017, 35 (03) : 390 - 400
  • [26] Is Tofacitinib Effectiveness in Patients with Rheumatoid Arthritis Better After Conventional Than After Biological Therapy? - A Cohort Study in a Colombian Population
    Santos -Moreno, Pedro
    Martinez, Susan
    Ibata, Linda
    Villarreal, Laura
    Rodriguez-Florido, Fernando
    Rivero, Manuel
    Rojas-Villarraga, Adriana
    Galarza-Maldonado, Claudio
    BIOLOGICS-TARGETS & THERAPY, 2022, 16 : 107 - 117
  • [27] Efficacy and Safety Of Tofacitinib In Older and Younger Patients With Rheumatoid Arthritis
    Curtis, J. R.
    Schulze-Koops, H.
    Takiya, L.
    Mebus, C. A.
    Terry, K.
    Chew, R.
    Jones, T. V.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S994 - S995
  • [28] Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study
    Kosuke Ebina
    Toru Hirano
    Yuichi Maeda
    Wataru Yamamoto
    Motomu Hashimoto
    Koichi Murata
    Akira Onishi
    Sadao Jinno
    Ryota Hara
    Yonsu Son
    Hideki Amuro
    Tohru Takeuchi
    Ayaka Yoshikawa
    Masaki Katayama
    Keiichi Yamamoto
    Makoto Hirao
    Yasutaka Okita
    Atsushi Kumanogoh
    Ken Nakata
    Clinical Rheumatology, 2021, 40 : 2673 - 2680
  • [29] Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study
    Ebina, Kosuke
    Hirano, Toru
    Maeda, Yuichi
    Yamamoto, Wataru
    Hashimoto, Motomu
    Murata, Koichi
    Onishi, Akira
    Jinno, Sadao
    Hara, Ryota
    Son, Yonsu
    Amuro, Hideki
    Takeuchi, Tohru
    Yoshikawa, Ayaka
    Katayama, Masaki
    Yamamoto, Keiichi
    Hirao, Makoto
    Okita, Yasutaka
    Kumanogoh, Atsushi
    Nakata, Ken
    CLINICAL RHEUMATOLOGY, 2021, 40 (07) : 2673 - 2680
  • [30] Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis
    Megan E. B. Clowse
    Steven R. Feldman
    John D. Isaacs
    Alexandra B. Kimball
    Vibeke Strand
    Richard B. Warren
    Daniel Xibillé
    Yan Chen
    Donald Frazier
    Jamie Geier
    James Proulx
    Amy Marren
    Drug Safety, 2016, 39 : 755 - 762